FDA, AstraZeneca, and Amgen: AI and Cloud for Clinical Trials

The FDA Embraces AI to Transform Clinical Trials

The United States Food and Drug Administration (FDA) has recently announced an ambitious pilot program in collaboration with pharmaceutical giants AstraZeneca and Amgen. This project aims to integrate artificial intelligence (AI) and cloud computing into the monitoring of clinical trials. The goal is to enable real-time data surveillance, which could revolutionize the way drugs are approved.

Traditionally, the drug approval process is lengthy and cumbersome, requiring extensive document submissions. Currently, it takes between ten and twelve years to bring a new drug to market. Approximately 45% of the time between the first clinical phase and regulatory submission is spent on paperwork and administrative tasks. With this new system, the FDA hopes to reduce these timelines by 20 to 40% by replacing documents with direct data streams. This advancement could significantly accelerate the market entry of new treatments.

An Internal AI Tool to Optimize Processes

The adoption of AI within the FDA does not stop there. More than 80% of the staff now uses an internal AI tool named Elsa. This tool has been designed to facilitate administrative tasks, allowing for reading, writing, and summarizing reports much more efficiently. While the use of Elsa has reduced the time for certain tasks from ten days to just 20 minutes, some issues have been reported. Indeed, Elsa has occasionally generated fictitious studies, raising questions about the reliability of AI tools.

A Strategic Turning Point After Budget Cuts

This pilot program comes amid severe budget constraints. Under the Trump administration and DOGE, the FDA faced significant cuts, resulting in mass layoffs in early 2025. Despite these challenges, the FDA has managed to save approximately $120 million per year. These savings are expected to allow for the re-hiring of up to 3,000 scientists, thereby strengthening the agency's capabilities.

FDA Commissioner Marty Makary emphasized the importance of this initiative, calling it a milestone in the agency's history. The idea of using AI to modernize the drug review process emerged last summer, in response to a system that has not evolved much since the 1960s.

Towards the Modernization of Clinical Trials

Jeremy Walsh, the FDA's AI lead, expressed optimism about the potential impact of this new approach. He stated that while the review process is being modernized, safety standards will not be compromised. The FDA has also launched a public request for information to explore other proposals aimed at improving clinical trials through AI.

This pilot project with AstraZeneca and Amgen could very well be the first step towards a radical transformation of the pharmaceutical industry, making the drug approval process faster and potentially more efficient.